Exane Derivatives’s Andeavor ANDV Stock Holding History

Exane Derivatives’s Portfolio ANDV Stock Details ANDV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-86	Closed	-$13.2K	–	767
2018 Q3	$13.2K	Hold	86	–	–	﹤0.01%	433
2018 Q2	$11.4K	Hold	86	–	–	﹤0.01%	455
2018 Q1	$8.58K	Hold	86	–	–	﹤0.01%	424
2017 Q4	$9.83K	Hold	86	–	–	﹤0.01%	403
2017 Q3	$8.87K	Hold	86	–	–	﹤0.01%	400
2017 Q2	$8.05K	Hold	86	–	–	﹤0.01%	413
2017 Q1	$6.97K	Hold	86	–	–	﹤0.01%	367
2016 Q4	$7.52K	Hold	86	–	–	﹤0.01%	418
2016 Q3	$6.84K	Hold	86	–	–	﹤0.01%	429
2016 Q2	$6.44K	Sell	86 -168	-66%	-$13.3K	﹤0.01%	387
2016 Q1	$21.8K	Sell	254 -304	-54%	-$26.1K	﹤0.01%	371
2015 Q4	$58.8K	Hold	558	–	–	0.01%	251
2015 Q3	$54.3K	Sell	558 -1,565	-74%	-$152K	0.01%	257
2015 Q2	$179K	Sell	2,123 -118	-5%	-$10.2K	0.02%	214
2015 Q1	$205K	Sell	2,241 -2,411	-52%	-$202K	0.02%	205
2014 Q4	$346K	Buy	+4,652	New	+$328K	0.05%	168

Other funds holding ANDV

SEI Investments Oaks, Pennsylvania $113B AUM 34.64% 1-Year Est. Return

Capital Innovations Pewaukee, Wisconsin $385M AUM

AWM

Alterna Wealth Management Houston, Texas $174M AUM 15.45% 1-Year Est. Return

Claro Advisors Boston, Massachusetts $953M AUM 24.79% 1-Year Est. Return

Exane Derivatives's ANDV Position: Q4 2018 in Review

Exane Derivatives sold out of Andeavor (ANDV) in Q4 2018, closing a stake of 86 shares — an estimated $13.2K sold.

Exane Derivatives first reported a position in ANDV in Q4 2014 and held it in 16 quarters. The position peaked at $346K in Q4 2014. 4 funds tracked by Wall St. Rank hold ANDV as of Q4 2018.

Exane Derivatives reported no remaining Andeavor position as of Q4 2018 after selling out during the quarter.
Exane Derivatives sold 86 Andeavor shares in Q4 2018, an estimated $13.2K.
Exane Derivatives first reported a position in Andeavor in Q4 2014 and held it in 16 quarters.
Exane Derivatives's Andeavor position peaked at $346K in Q4 2014.
4 funds tracked by Wall St. Rank held Andeavor as of Q4 2018.

Based on Exane Derivatives's 13F filing for Q4 2018, filed 31 Jan 2019.